Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CytoDyn Inc. stock logo
CYDY
CytoDyn
$0.25
+9.5%		$0.21
$0.18
▼
$0.40
$346.68M1.51.62 million shs6.38 million shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$9.36
+3.1%		$11.38
$7.36
▼
$13.90
$807.76M0.471.75 million shs2.16 million shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$2.42
-1.6%		$4.10
$2.38
▼
$29.98
$24.71M0.3174,924 shs23,365 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$447.09
-0.6%		$513.70
$393.61
▼
$615.00
$10.39B-1.04285,422 shs263,729 shs
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$3.33
+2.5%		$3.93
$1.29
▼
$5.08
$207.03M1.2643,200 shs567,614 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CytoDyn Inc. stock logo
CYDY
CytoDyn
+9.51%+25.00%+16.99%+23.15%-6.30%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+3.08%-10.00%-20.20%-14.05%-4.88%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-1.63%-9.70%-39.50%-53.90%-87.20%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-0.59%-4.30%-15.88%-18.23%+1.87%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
+2.46%-10.48%-19.57%-26.65%+101.82%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CytoDyn Inc. stock logo
CYDY
CytoDyn
$0.25
+9.5%		$0.21
$0.18
▼
$0.40
$346.68M1.51.62 million shs6.38 million shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$9.36
+3.1%		$11.38
$7.36
▼
$13.90
$807.76M0.471.75 million shs2.16 million shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$2.42
-1.6%		$4.10
$2.38
▼
$29.98
$24.71M0.3174,924 shs23,365 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$447.09
-0.6%		$513.70
$393.61
▼
$615.00
$10.39B-1.04285,422 shs263,729 shs
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$3.33
+2.5%		$3.93
$1.29
▼
$5.08
$207.03M1.2643,200 shs567,614 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CytoDyn Inc. stock logo
CYDY
CytoDyn
+9.51%+25.00%+16.99%+23.15%-6.30%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+3.08%-10.00%-20.20%-14.05%-4.88%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-1.63%-9.70%-39.50%-53.90%-87.20%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-0.59%-4.30%-15.88%-18.23%+1.87%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
+2.46%-10.48%-19.57%-26.65%+101.82%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CytoDyn Inc. stock logo
CYDY
CytoDyn
0.00
N/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.77
Moderate Buy$25.35170.86% Upside
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
2.25
Hold$17.00602.48% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.78
Moderate Buy$699.2056.39% Upside
MacroGenics, Inc. stock logo
MGNX
MacroGenics
2.17
Hold$6.3390.19% Upside

Current Analyst Ratings Breakdown

Latest MDGL, MGNX, MCRB, KURA, and CYDY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/15/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/14/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight
10/14/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$735.00
10/14/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$24.00
10/14/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$24.00
10/14/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingMarket Outperform
10/5/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/1/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOverweight$30.00
9/24/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$704.00
9/24/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$704.00
(Data available from 10/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/AN/AN/AN/A($0.08) per shareN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$67.48M12.34N/AN/A$2.00 per share4.68
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$790K30.79$1.07 per share2.26$4.89 per share0.49
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M10.78N/AN/A$26.54 per share16.85
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$149.50M1.42N/AN/A$0.88 per share3.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CytoDyn Inc. stock logo
CYDY
CytoDyn
-$42.70M-$0.03N/AN/AN/AN/AN/A-268.00%N/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$278.67M-$3.37N/AN/AN/A-384.30%-207.18%-45.17%11/3/2026 (Estimated)
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$5.70M-$2.43N/AN/AN/A-1,192.94%-114.82%-34.15%11/4/2026 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A83.10N/A-25.32%-56.65%-25.53%11/3/2026 (Estimated)
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$74.62M-$0.22N/AN/AN/A-8.70%-109.26%-18.70%11/11/2026 (Estimated)

Latest MDGL, MGNX, MCRB, KURA, and CYDY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2026Q3 2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$0.10N/AN/AN/A$39.18 millionN/A
11/4/2026Q3 2026
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$1.0050N/AN/AN/A$6.35 millionN/A
11/3/2026Q3 2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.8144N/AN/AN/A$24.86 millionN/A
11/3/2026Q3 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$0.8345N/AN/AN/A$405.27 millionN/A
10/14/2026Q1 2027
CytoDyn Inc. stock logo
CYDY
CytoDyn
-$0.05-$0.01+$0.04-$0.01N/AN/A
8/13/2026Q2 2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$0.0779$0.31+$0.3879$0.31$59.14 million$32.83 million
8/12/2026Q2 2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.8773-$0.77+$0.1073-$0.77$20.16 million$20.87 million
8/5/2026Q2 2026
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$2.18$0.47+$2.65$0.47$0.18 million$0.74 million
7/30/2026Q2 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$2.68-$1.99+$0.69-$1.99$352.13 million$364.25 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/AN/AN/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/A
0.38
0.38
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.12
4.73
4.71
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/A
2.11
2.11
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/A
2.96
2.96

Institutional Ownership

CompanyInstitutional Ownership
CytoDyn Inc. stock logo
CYDY
CytoDyn
5.06%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
59.34%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
96.89%

Insider Ownership

CompanyInsider Ownership
CytoDyn Inc. stock logo
CYDY
CytoDyn
1.00%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
7.60%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
5.20%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
13.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
CytoDyn Inc. stock logo
CYDY
CytoDyn
141.52 billion1.50 billionNot Optionable
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
26088.96 million82.20 millionOptionable
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
6610.05 million9.52 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
91523.10 million19.04 millionOptionable
MacroGenics, Inc. stock logo
MGNX
MacroGenics
29363.70 million55.04 millionOptionable

Recent News About These Companies

Six brokers set USD 6.33 target for MacroGenics stock
October 17 at 9:12 PM  |  ad-hoc-news.deA
MacroGenics, Inc. (MGNX) - What Are Brokerages Thinking About This Stock?
October 17 at 4:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-macrogenics-inc-mgnx-what-are-brokerages-thinking-about-this-stock-2026-10-17/
MacroGenics, Inc. Announces First Patient Dosed In Phase 1 Study Of MGC030 In Patients With Advanced Solid Tumors
October 16, 2026  |  marketscreener.comM
MacroGenics doses first patient in Phase 1 trial of MGC030 ADC
October 16, 2026  |  streetinsider.comhttps://www.streetinsider.com/FDA/MacroGenics+doses+first+patient+in+Phase+1+trial+of+MGC030+ADC/27193349.html
MacroGenics stock has October 23 data ahead in 2026
October 15, 2026  |  ad-hoc-news.deA
MacroGenics Says First Patient Dosed in Phase 1 Study of MGC030 for Advanced Solid Tumors
October 15, 2026  |  marketscreener.comM
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
October 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/15/3382129/0/en/macrogenics-announces-first-patient-dosed-in-phase-1-study-of-mgc030-in-patients-with-advanced-solid-tumors.html
Financial Review: Madrigal Pharmaceuticals (NASDAQ:MDGL) & MacroGenics (NASDAQ:MGNX)
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31106040
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
October 9, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3003686/is-macrogenics-mgnx-stock-outpacing-its-medical-peers-this-year?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_1-3003686
MacroGenics insider exercises 8,000 options for MacroGenics stock
October 9, 2026  |  ad-hoc-news.deA
MacroGenics stock fell 2.47 percent on October 7 with pipeline data ahead
October 7, 2026  |  ad-hoc-news.deA
MacroGenics stock faces October data after a Q2 revenue miss
October 5, 2026  |  ad-hoc-news.deA
2,488,252 Shares in MacroGenics, Inc. $MGNX Acquired by Bank of America Corp DE
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-2488252-shares-in-macrogenics-inc-mgnx-acquired-by-bank-of-america-corp-de-2026-09-26/
MacroGenics stock holds at USD 4.12 as cash strength stands out
September 23, 2026  |  ad-hoc-news.deA
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Hold" from Analysts
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-macrogenics-inc-nasdaq-mgnx-receives-consensus-recommendation-of-hold-from-analysts-2026-09-22/
MacroGenics stock edges lower as biotech analysts highlight risk and upside
September 19, 2026  |  ad-hoc-news.deA
MacroGenics consensus price target rises 12% to $9.52
September 14, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/macrogenics-consensus-price-target-rises-12-to-952/ar-AA2cbGur
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3359059/0/en/macrogenics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference.html
MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944341-macrogenics-inexpensive-adctce-biotech-with-multiple-catalysts-ahead
MacroGenics (NASDAQ:MGNX) VP Sells $129,085.75 in Stock
August 21, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-mgnx-insider-buying-and-selling-2026-08-21/
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
August 20, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2977528/is-macrogenics-mgnx-stock-outpacing-its-medical-peers-this-year?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_1-2977528

New MarketBeat Followers Over Time

Media Sentiment Over Time

CytoDyn stock logo

CytoDyn OTCMKTS:CYDY

$0.25 +0.02 (+9.51%)
As of 10/19/2026 03:59 PM Eastern

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Kura Oncology stock logo

Kura Oncology NASDAQ:KURA

$9.36 +0.28 (+3.08%)
Closing price 10/19/2026 04:00 PM Eastern
Extended Trading
$9.22 -0.14 (-1.49%)
As of 10/19/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Seres Therapeutics stock logo

Seres Therapeutics NASDAQ:MCRB

$2.42 -0.04 (-1.63%)
Closing price 10/19/2026 04:00 PM Eastern
Extended Trading
$2.42 +0.00 (+0.21%)
As of 10/19/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$447.09 -2.65 (-0.59%)
Closing price 10/19/2026 04:00 PM Eastern
Extended Trading
$444.17 -2.92 (-0.65%)
As of 10/19/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

MacroGenics stock logo

MacroGenics NASDAQ:MGNX

$3.33 +0.08 (+2.46%)
Closing price 10/19/2026 04:00 PM Eastern
Extended Trading
$3.32 0.00 (-0.15%)
As of 10/19/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas